Investigation Launched into Pacira Biosciences Buyout Offer Value
Ademi LLP is investigating the $1.65 billion cash acquisition of Pacira Biosciences ($PCRX), which offers shareholders $36.50 per share. The probe will examine the fairness of the deal price and potential benefits to company insiders.
Law firm Ademi LLP has initiated an investigation into the terms of the proposed buyout of Pacira Biosciences, Inc. ($PCRX). The transaction values the company at $1.65 billion, with shareholders set to receive $36.50 in cash for each share they own.
The investigation aims to determine whether the offer price of $36.50 per share accurately reflects the company's value and if the deal's terms are equitable for shareholders. A key focus will be on any potential benefits that may accrue to company insiders as a result of the acquisition.
Furthermore, Ademi LLP is scrutinizing contractual provisions that might restrict the company from considering competing acquisition offers. Such clauses could potentially prevent shareholders from securing a more favorable offer from alternative buyers.
Announced in Milwaukee on October 8, 2026, the investigation seeks to ensure that all shareholders receive fair compensation in connection with the sale of the company.